Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia

Abstract: Before November 2023, CD19 chimeric antigen receptor (CAR) T-cell therapies had not been approved in China for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), leaving a significant unmet need. In response, inaticabtagene autoleucel (Inati-cel), a novel...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Wang, Lulu Lv, Yongping Song, Xudong Wei, Hongsheng Zhou, Qifa Liu, Kailin Xu, Dongmei Yan, Cheng Zhang, Shuangyou Liu, Jie Jin, Heng Mei, Ting Niu, Aibin Liang, Runxia Gu, Jienan Ren, Yi Feng, Wei Jin, Yan Zhou, Yiping Deng, Jianxiang Wang
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006888
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006888

Similar Items